New protein signature of breast cancer progression identified

May 22, 2012

A protein signature that predicts overall survival in breast cancer patients has been uncovered in the most comprehensive survey of protein expression patterns in breast cancer progression to date.

The findings of the collaborative study led by the Max Planck Institute of Biochemistry, Germany and involving researchers in University College Dublin and the National Institute of Cellular Biotechnology, Dublin City University are published in the current issue of .

Breast cancer is the second leading cause of for women in the USA. Within the various subtypes of the disease, estrogen receptor negative (ER-) tumours have a relatively .

This study focused on identifying the proteins associated with the progression of ER- tumours and, of the 8750 proteins identified, 7800 were quantified. Proteomic analysis showed that high levels of proteins, CRABP2 and IDH2, along with low levels of SEC14L2 were predictive of overall breast cancer survival in patients.

The Irish contribution to the study, which involved Conway Fellow, Professor William Gallagher and Dr Stephen Madden (DCU), focused on the in silico validation of the candidate multi-marker signature of these 3 proteins (CRABP2, IDH2, SEC14L2).

‘As the initial discovery work by the Mann group in the Max Planck Institute was performed on a discrete set of cell culture models and clinical specimens, our work provided a key element of verification on more than 1,200 patients,”, said Professor Gallagher, Associate Professor of Cancer Biology, UCD School of Biomolecular and Biomedical Science and deputy coordinator of the SFI Molecular Therapeutics for Cancer Ireland Strategic Research Cluster. “We were also able to demonstrate that this prognostic signature retained value at the mRNA level, as the original discovery work was at the protein level”.

Commenting on the potential impact of the research, Professor Gallagher added, “The real strength of this work is that it will act as a very extensive repository for information for multiple investigators worldwide, thereby impacting on a wide range of downstream studies”.

Ideally, Gallagher and his team would hope to look at the functional relevance of the differentially expressed proteins identified in terms of their respective contributions to and to further validate using hundreds to thousands of clinical specimens that this 3-marker signature also works at the protein level.

Explore further: Personalising the use of chemotherapy in breast cancer treatment

More information: Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Tamar Geiger, Stephen F. Madden, William M. Gallagher, Juergen Cox and Matthias Mann, Cancer Research, May 1 2012 (first published online Mar 12)

Related Stories

Personalising the use of chemotherapy in breast cancer treatment

December 15, 2011
(Medical Xpress) -- UCD researchers have identified a novel biomarker that can identify those women with breast cancer who will have a poor response to tamoxifen, one of the principle anti-hormone drugs used to treat the ...

Scientists identify natural defence cells that impede chemotherapy treatment

April 27, 2011
As part of the body’s front-line defences against infection, white blood cells called macrophages often infiltrate tumours in great numbers. However, according to new research published in the scientific journal Cancer ...

Researchers identify new genes that determine breast cancer prognosis

September 26, 2011
Researchers at Wake Forest Baptist Medical Center have made a discovery that brings them one step closer to being able to better predict which patients have the best chance of surviving breast cancer.

Cellular 'glue' resists breast cancer

April 20, 2012
Early detection and advances in the treatment for breast cancer have improved the chances of survival, however new avenues for treatment are still needed in the battle against this disease. New research published in BioMed ...

Recommended for you

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

Combining CAR T cells with existing immunotherapies may overcome resistance in glioblastomas

July 19, 2017
Genetically modified "hunter" T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

New way found to boost immunity in fight cancer and infections

July 19, 2017
An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemont Hospital Research Centre, has identified a key ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.